Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2655MR)

This product GTTS-WQ2655MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2655MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5073MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ6593MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ756MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ12415MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ4911MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ14205MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ14793MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ8863MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IDEC-C2B8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW